Data layers Raw facts Calculated Model prediction AI interpretation

IPO Timeline Raw facts

Broker Deadline
Morning deadline
HKEX Deadline
Noon deadline
Broker Results (T-2)
Some brokers release in afternoon
Grey Market (T-1)
Afternoon
HKEX Allotment (T-1)
Evening
Registrar Allotment (T-1)
Evening
Listing Day (T)
First day of trading

Company Overview

Stock NameTransthera-B
Stock Code02617
Company Full NameTransThera Sciences (Nanjing), Inc.
Industry醫療保健
Principal Activities公司是一家以臨床需求為導向、處于注冊臨床階段的生物制藥公司,專注于發現及開發腫瘤、炎癥及心臟代謝疾病小分子創新療法。
Listing Date2025-06-23
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國江蘇省南京市江北新區生物醫藥谷加速器二期9棟3樓
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitehttps://www.transthera.com/En/Index/index
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism 18A生物科技
Offer PriceHK$ 13.15 / shares
Offer Price RangeFinal offer price only, no range
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2025-06-13 to 2025-06-18
Global Offering Shares15,281,000 shares
HK Public Offer Shares (Initial)To be extracted
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)To be extracted
Offer RatioTo be extracted
Total Shares Post-IPOTo be extracted
Greenshoe (Over-allotment Option)No
Stabilizing Manager (Greenshoe)—
Cornerstone Share64.0%
Clawback TiersTo be extracted
Reallocation OptionNo
Total Global Offering SizeHK$ 200,945,150

Stock Connect Inclusion Analysis

HK Market Cap HK$ 10.87B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss StatusTo be extracted
Period-End Cash BalanceRMB 569.5 million
Listing Expenses~HK$ 36,300,000
Listing Expenses / Funds Raised~19.7%
Total Pre-IPO Investmentapproximately RMB 1,723 million
First Day CloseHK$ 23.5
First Day OpenHK$ 21.65
First Day Change78.71%
First Day Volume8541000.0
First Day Turnover191298000.0
Use of Proceeds
1、約90.0%或145.2百萬港元將用于為我們的核心產品Tinengotinib正在進行單藥治療CCA的多區域注冊III期臨床試驗提供資金; 2、約10.0%或16.1百萬港元將分配用于我們的一般營運資金及一般公司用途。

Underwriting Syndicate

Joint Sponsors (2)
中信证券(香港)有限公司 CE AAK249 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
Sponsor cum Overall Coordinator (2)
CLSA LIMITED CE AAB893 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
Overall Coordinators (3)
CLSA LIMITED CE AAB893 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 交银国际证券有限公司 CE APJ121
Joint Global Coordinators (3)
CLSA LIMITED CE AAB893 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 交银国际证券有限公司 CE APJ121
Joint Bookrunners (7)
CLSA LIMITED CE AAB893 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 交银国际证券有限公司 CE APJ121 中银国际亚洲有限公司 CE AET863 招银国际融资有限公司 CE AVM940 SPDB International Capital Limited CE BFZ375 TradeGo Markets Limited CE BRO637
Joint Lead Managers (7)
CLSA LIMITED CE AAB893 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 交银国际证券有限公司 CE APJ121 中银国际亚洲有限公司 CE AET863 招银国际融资有限公司 CE AVM940 SPDB International Capital Limited CE BFZ375 TradeGo Markets Limited CE BRO637
Capital Market Intermediaries (7)
CLSA LIMITED CE AAB893 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 交银国际证券有限公司 CE APJ121 中银国际亚洲有限公司 CE AET863 招银国际融资有限公司 CE AVM940 SPDB International Capital Limited CE BFZ375 TradeGo Markets Limited CE BRO637

Service Providers

RoleInstitution
Legal Advisor to Company 美迈斯律师事务所
嘉源律师事务所
Legal Advisor to Sponsors/Underwriters 盛德律师事务所
竞天公诚律师事务所
Auditor and Reporting Accountant 安永会计师事务所
Industry Advisor 弗若斯特沙利文(北京)咨询有限公司上海分公司
Receiving Banks 招商永隆银行有限公司
中国银行(香港)有限公司

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 华盛敦行有限公司 21,592,300 HKD — 10.75% — 6 months 2025-12-23
2 江北医药科技(香港)有限公司 75,487,575 HKD — 37.57% — 6 months 2025-12-23
3 康方生物科技(开曼)有限公司 9,895,375 HKD — 4.92% — 6 months 2025-12-23
4 科瓴安(香港)科技有限公司 10,750,125 HKD — 5.35% — 6 months 2025-12-23
5 药石地平线资本有限公司 10,802,725 HKD — 5.38% — 6 months 2025-12-23

Directors & Management

PositionChinese nameEnglish Name
Chairman吳永謙—
Company Secretary馮潔,黃荻—
No director data available.

Major Shareholders

Major Shareholders & Holdings南京益鏷生物科技合伙企業(有限合伙)(13.79%),吳永謙(12.06%),南京吉旻瑞生物科技合伙企業(有限合伙)(7.13%),基科發展有限公司(6.96%),先進制造產業投資基金二期(有限合伙)(6.12%)
About this page

This page shows Transthera-B (02617) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect